RecruitingPHASE1, PHASE2NCT06083207

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Studying Mucolipidosis type II

Last synced from ClinicalTrials.gov May 13, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Intervention: IBI3003(drug)
Enrollment: 116 enrolled
Eligibility: 18 years · All sexes
Timeline: 2024 – 2027

Study locations (13)

Wollongong Private Hospital, Wollongong, New South Wales, Australia
Austin Hospital, Heidelberg, Victoria, Australia
St Vincent's Hospital, Melbourne, Victoria, Australia
Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
The first Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Tongji Medical College of HUST Tongji Hospital, Wuhan, Hubei, China
Jiangsu Province Hospital, Nanjing, Jiangsu, China
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
Jiangxi Cancer Hospital, Nanchang, Jiangxi, China
ZhongShan Hospital FuDan University, Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of XI'AN Jiaotong University, Xian, Shanxi, China
Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06083207 on ClinicalTrials.gov

Other trials for Mucolipidosis type II

Additional recruiting or active studies for the same condition.

See all trials for Mucolipidosis type II →

← Back to all trials